Provided by Tiger Trade Technology Pte. Ltd.

Intensity Therapeutics, Inc.

0.3490
+0.01023.01%
Post-market: 0.39020.0412+11.81%19:58 EST
Volume:486.51K
Turnover:168.99K
Market Cap:20.96M
PE:-0.68
High:0.3550
Open:0.3477
Low:0.3401
Close:0.3388
52wk High:2.53
52wk Low:0.1853
Shares:60.06M
Float Shares:53.76M
Volume Ratio:0.49
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5114
EPS(LYR):-1.1698
ROE:-234.70%
ROA:-101.66%
PB:2.90
PE(LYR):-0.30

Loading ...

Company Profile

Company Name:
Intensity Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
6
Office Location:
1 Enterprise Drive,Suite 430,Shelton,Connecticut,United States
Zip Code:
06484-4779
Fax:
203 557 3023
Introduction:
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Directors

Name
Position
Lewis H. Bender
President, Chief Executive Officer and Chairman of the Board
Daniel Donovan
Director
Emer Leahy
Director
Mark A. Goldberg
Director

Shareholders

Name
Position
Lewis H. Bender
President, Chief Executive Officer and Chairman of the Board
John Wesolowski
Interim Chief Financial Officer, Principal Accounting Officer and Controller
James M. Ahlers
Executive Vice President of Corporate Finance